{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:16:16Z","timestamp":1791404176381,"version":"4.3.3"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,2,10]],"date-time":"2006-02-10T00:00:00Z","timestamp":1139529600000},"content-version":"vor","delay-in-days":1532,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> A thorough review of the clinical trial data combined with new <jats:italic>in vitro<\/jats:italic> experimental information may make the optimization of dosages of TB drugs possible. Several factors can affect the selection and dosage of TB drugs including hepatic and renal impairment, pregnancy, duration of disease before treatment, and extent of debilitation. Drug interactions and pharmacodynamics must be considered, and their roles are discussed.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2001.tb11374.x","type":"journal-article","created":{"date-parts":[[2006,2,10]],"date-time":"2006-02-10T17:48:54Z","timestamp":1139593734000},"page":"157-164","source":"Crossref","is-referenced-by-count":57,"title":["Pharmacological Issues in the Treatment of Tuberculosis"],"prefix":"10.1111","volume":"953b","author":[{"given":"CHARLES A.","family":"PELOQUIN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,2,10]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835020-00004"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-5231(05)70357-9"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/514623"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/514620"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/514622"},{"key":"e_1_2_10_7_2","doi-asserted-by":"crossref","unstructured":"Bartmann K. 1988. Antituberculosis Drugs. Springer\u2010Verlag. Berlin.","DOI":"10.1007\/978-3-642-72873-0"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302253280802"},{"key":"e_1_2_10_9_2","unstructured":"Berning S.E. & C.A. Peloquin. 1998. Antimycobacterial agents: cycloserine.InAntimicrobial Chemotherapy. V.L. Yuet al.Eds.: 638\u2013642. Williams and Wilkins. Baltimore MD."},{"key":"e_1_2_10_10_2","unstructured":"Berning S.E. & C.A. Peloquin. 1998. Antimycobacterial agents: ethionamide.InAntimicrobial Chemotherapy. V.L. Yuet al.Eds.: 650\u2013654. Williams and Wilkins. Baltimore MD."},{"key":"e_1_2_10_11_2","unstructured":"Peloquin C.A. 1991. Antituberculosis drugs: pharmacokinetics.InDrug Susceptibility in the Chemotherapy of Mycobacterial Infections. L. Heifets Ed.: 59\u201388. CRC Press. Boca Raton FL."},{"key":"e_1_2_10_12_2","unstructured":"McEvoy G.K. Ed. 2001. AHFS Drug Information. American Society of Hospital Pharmacists. Bethesda MD."},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.4.984"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/515174"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/318490"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803030-00002"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.1.320"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936020-00001"},{"key":"e_1_2_10_20_2","first-page":"18","article-title":"Routine monitoring of serum vancomycin concentrations: the answer lies in the middle","volume":"7","author":"Sayers JFB","year":"1988","journal-title":"Clin Pharmocol"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/18.4.533"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/18.4.544"},{"key":"e_1_2_10_23_2","unstructured":"Piscitelli S.C. 2001. The value of drug levels: the plot thickens. Medscape.http:\/\/id.medscape.com\/Medscape\/CNO\/2001\/RETRO\/Story.cfm?story_id=2055"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/322706"},{"key":"e_1_2_10_25_2","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1128\/AAC.43.10.2473","article-title":"Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo","volume":"43","author":"Mouton JW","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310073291513"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199502023320518"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200006000-00016"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.149.5.8173779"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2001.tb11374.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2001.tb11374.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T13:47:29Z","timestamp":1695649649000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2001.tb11374.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1111\/j.1749-6632.2001.tb11374.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb11374.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}